Di Bisceglie said the antiviral drug interferon had reduced symptoms in up to 20 percent of patients with hepatitis C who were treated for six months.
The Food and Drug Administration approved a powerful combination of two antiviral drugs to treat chronic hepatitis C, a liver infection that can lead to cirrhosis, liver cancer and liver failure.
Because of the risks of treatment, and its partial success rate, doctors have tried to determine which patients truly need it rather than just giving the drugs to everyone with hepatitis C. Only 20 percent to 30 percent of people with chronic infections develop cirrhosis, liver failure or cancer.
A standard AIDS drug appears to slow liver damage caused by hepatitis B. A study in Thursday's New England Journal of Medicine looked at the effects of the drug 3TC on people with long-standing infections with the virus.
The AIDS groups began showing hepatitis patients how to do battle with big drug companies.
Consalvo, said Schering-Plough has listened to the concerns of patient advocates and is developing a program to help provide ribavirin to hepatitis patients whose doctors can prove that the patients have a need for it.
Fisher's Specialized Pharmacy Services in Pittsburgh has announced plans to fill prescriptions nationwide for the anti-viral drug ribavirin, used by growing numbers of hepatitis C patients in combination with the drug interferon.
Only one-third of patients who gave themselves weekly thigh injections of the drug developed MS within three years, compared with half the patients who
